ROCHESTER, N.Y., May 31 /PRNewswire/ -- VirtualScopics, Inc. , a leading developer of image-related biomarkers, today announced it has received approval for listing on the Nasdaq Capital Market. The company’s common stock will begin trading on the Nasdaq today under the symbol “VSCP.” The company’s common stock previously traded on the OTC Electronic Bulletin Board.
“We are extremely pleased by the approval of our listing on Nasdaq. We believe that it will broaden our investor base with additional brokers, funds and money managers while increasing our visibility in the financial community and providing our stockholders with a more liquid and efficient market in which to trade our shares,” stated Robert Klimasewski, president and CEO of VirtualScopics. “The Nasdaq listing is one more milestone in the company’s evolution as a public company. This event, along with our continued progress working with ten of the top fifteen global pharmaceutical companies, is evidence of the company’s development.”
About VirtualScopics, Inc.
VirtualScopics, Inc. is a provider of advanced medical image analysis services. The company evolved from research first carried out at the University of Rochester Medical Center and School of Engineering. VirtualScopics has created a suite of image analysis tools used in detecting and analyzing specific structures in volumetric medical images, as well as characterizing minute changes in structures over time, providing vital information to support clinical trials and diagnostic applications. The firm’s proprietary software algorithms can assemble hundreds of separate medical images taken during an MRI session into a single, three-dimensional model, bringing a new and previously unobtainable source of data to clinical researchers. For more information about VirtualScopics, visit www.virtualscopics.com.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the awards of a potential contract from the U.S. Department of Defense and the expected benefits to the Company from that award and its existing contract with Pfizer and/or statements preceded by, followed by or that include the words “believes,” “could,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “projects,” “seeks,” or similar expressions. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company’s Current Report on Form 8-K for November 4, 2005 filed with the Securities and Exchange Commission (the “SEC”), and in any subsequent reports filed with the SEC, all of which are available at the SEC’s website at www.sec.gov. These include without limitation: risks related to the dependence on our strategic alliance with Pfizer until we can diversify our customer base; risks of contract performance; risks of contract termination; and, our ability to successfully enter into a contract with the Department of Defense for the award we obtained and our ability to do so on terms favorable to us. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.
CONTACT: Tracy Bagatelle-Black Bagatelle-Black Public Relations 661/263-1842 tracy@bagatelleblack.com
VirtualScopics, LLC
CONTACT: Tracy Bagatelle-Black of Bagatelle-Black Public Relations forVirtualScopics, Inc., +1-661-263-1842 or tracy@bagatelleblack.com
Web site: http://www.virtualscopics.com//
